[1] Mok TS,Wu YL,Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361(10):947-957.

[2] Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens foradvanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.

[3] Ascierto PA,Addeo R,Cartenì G,et al.The role of immunotherapy in solid tumors:report from the Campania Society of Oncology Immunotherapy (SCITO) meeting,Naples 2014[J].J Transl Med,2014,12:291.

[4] 林城,陈雄,刘静南,等.PD-1/PD-L1信号通路在非小细胞肺癌免疫逃逸及其治疗中的研究进展[J].中国肺癌杂志,2014,17(10):734-740.

[5] Mu CY,Huang JA,Chen Y,et al.High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation[J].Med Oncol,2011,3(28):682-688.

[6] Boland JM,Kwon ED,Harrington SM,et al.Tumor B7-H1 and B7-H3 expression in squamouscell carcinoma of the lung[J].Clin Lung Cancer,2013,14(2):157-163.

[7] 周支瑞,张天嵩,李博,等.生存曲线中Meta分析适宜数据的提取与转换[J].中国循证心血管医学杂志,2014,6(3):243-247.

[8] Tierney JF,Stewart LA,Ghersi D,et al.Practical methods for incorporating summary time-to-event data into meta-analysis[J].Trials,2007,8(16).doi:10.1186/1745-6215-8-16.

[9] Yang CY,Lin MW,Chang YL,et al.Programmed cell death-ligand 1 expression in surgically resected stage Ⅰ pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes[J].Eur J Cancer,2014 (50):1361-1369.

[10] Velchetii V,Schalper KA,Carvajal DE,et al.Programmed death ligand-1 expression in non-small cell lung cancer[J].Lab Invest,2014,94(1):107-116.

[11] Zhang Y,Wang L,Li Y,et al.Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma[J].OncolTargets Ther,2014(7):567-573.

[12] Azuma K,Ota K,Kawahara A,et al.Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer[J].Ann Oncol,2014(25):1935-1940.

[13] Ishii H,Azuma K.Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer[J].J Thorac Oncol,2015,doi:10.1097/JTO.0000000000000414.

[14] 马薇,罗殿中,陈源,等.PD-L1和PD-1在非小细胞肺癌中的表达及其临床意义[J].实用医学杂志,2011,27(9):1551-1554.

[15] Chen YB,Mu CY,Huang JA.Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer:a 5-year-follow-up study[J].Tumor,2012,98(6):751-755.

[16] Freeman GJ,Long AJ,Iwai Y,et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 familymember leadstonegativeregulationof lymphocyteactivation[J]. J Exp Med,2000,192(7):1027-1034.

[17] Dong H,Strome SE,Salomao DR,et al.Tumor-associated B7-H1 promotes T-ell apoptosis:a potential mechanism of immune evasion[J].Nat Med,2002,8(8):793-800.

[18] Topalian SL,Drake CG,Pardoll DM.Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity[J].Curr Opin Immunol,2012,24(2):207-212.

[19] Iwai Y,Ishida M,Tanaka Y,et al.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J].Proc Natl Acad Sci U S A,2002,99(19):12293-12297.